Back to Top Skip to main content

Health.mil: the official website of the Military Health System (MHS) and the Defense Health Agency (DHA)

Utility Navigation Links

TRICARE Policy Manual 6010.60-M, April 1, 2015
Medicine
Chapter 7
Section 2.7
Hydration, Therapeutic, Prophylactic, And Diagnostic Injections And Infusions
Issue Date:  
Copyright:  CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.
Revision:  C-1, March 10, 2017
1.0  CPT PROCEDURE CODES
96360 - 96379
2.0  HCPCS PROCEDURE CODES
J2357, J3487, J3488
3.0  DESCRIPTION
Intravenous (IV) hydration infusion consists of pre-packaged fluid and electrolytes, but not infusion of drugs or other substances. A therapeutic, prophylactic, or diagnostic IV infusion or injection (other than hydration) is for the administration of substances or drugs.
Note:  Policy regarding chemotherapy administration is found in Section 16.3.
4.0  POLICY
4.1  Hydration IV infusion consisting of a pre-packaged fluid and electrolytes is covered.
4.2  Intravenous or intra-arterial push (an injection in which the health care professional who administers the substance/drug is continuously present to administer the injection and observe the patient or an infusion of 15 minutes or less) for therapy, prophylactic, or diagnosis is covered.
4.3  Off-label use of zoledronic acid (Zometa®) for the treatment of breast cancer may be cost-shared when:
4.3.1  Patient was premenopausal at the time of diagnosis, and has stage I or II breast cancer;
4.3.2  Patient has had surgically induced menopause (e.g., oophorectomy) or has been put temporarily into menopause (chemically induced menopause with Goserelin or similar product) prior to administration of zoledronic acid;
4.3.3  Patient has hormone receptor (Estrogen Receptor (ER) and/or Progesterone Receptor (PR)) positive disease and zoledronic acid is being used in combination with hormonal therapy (e.g., Tamoxifen, Arimedex®, Aromasin®, Femara®);
4.3.4  No concurrent adjuvant chemotherapy has been given or planned;
4.3.5  Prescriber is an oncologist or an individual highly familiar with prescribing and monitoring of oncology-related medications.
4.3.6  Off-label use of omalizumab (Xolair®) for the treatment of chronic urticaria may be cost-shared.
5.0  EFFECTIVE Dates
5.1  February 12, 2009, for off-label use of zoledronic acid (Zometa®) for the treatment of breast cancer.
5.2  July 1, 2011, for off-label use of omalizumab (Xolair®) for the treatment of chronic urticaria.
- END -

Utility Navigation Links

DoD Seal

tricare.mil is the offical website of the Defense Health Agency (DHA) a component of the Military Health System

TRICARE is a registered trademark of the Department of Defense (DoD), DHA. All rights reserved.

CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

If you have a question regarding TRICARE benefits, please go to the TRICARE Contact Us page page.
If you need help with technical/operational issues, please go to the TRICARE Manuals Online Help Resources page.

The appearance of hyperlinks to external websites does not constitute endorsement by the DHA of these websites or the information, products or services contained therein. For other than authorized government activities, the DHA does not exercise any editorial control over the information you may find at other locations. Such links are provided consistent with the stated purpose of this DoD website.

v4.5.7082.22297

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.